Author: Hu, Fuqing; Song, Da; Yan, Yumeng; Huang, Changsheng; Shen, Chentao; Lan, Jingqin; Chen, Yaqi; Liu, Anyi; Wu, Qi; Sun, Li; Xu, Feng; Hu, Fayong; Chen, Lisheng; Luo, Xuelai; Feng, Yongdong; Huang, Shengyou; Hu, Junbo; Wang, Guihua
                    Title: IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation  Cord-id: l6busnbc  Document date: 2021_6_15
                    ID: l6busnbc
                    
                    Snippet: Extracellular cytokines are enriched in the tumor microenvironment and regulate various important properties of cancers, including autophagy. However, the precise molecular mechanisms underlying the link between autophagy and extracellular cytokines remain to be elucidated. In the present study, we demonstrate that IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway and promotes chemotherapy resistance in colorectal cancer (CRC). Mechanistically, IL-6 triggers the interaction between JA
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: Extracellular cytokines are enriched in the tumor microenvironment and regulate various important properties of cancers, including autophagy. However, the precise molecular mechanisms underlying the link between autophagy and extracellular cytokines remain to be elucidated. In the present study, we demonstrate that IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway and promotes chemotherapy resistance in colorectal cancer (CRC). Mechanistically, IL-6 triggers the interaction between JAK2 and BECN1, where JAK2 phosphorylates BECN1 at Y333. We demonstrate that BECN1 Y333 phosphorylation is crucial for BECN1 activation and IL-6-induced autophagy by regulating PI3KC3 complex formation. Furthermore, we investigate BECN1 Y333 phosphorylation as a predictive marker for poor CRC prognosis and chemotherapy resistance. Combination treatment with autophagy inhibitors or pharmacological agents targeting the IL-6/JAK2/BECN1 signaling pathway may represent a potential strategy for CRC cancer therapy.
 
  Search related documents: 
                                Co phrase  search for related documents- acidic environment and lysosome fusion: 1
- activation release and low expression: 1, 2
- activation release and lung cancer: 1, 2
 
                                Co phrase  search for related documents, hyperlinks ordered by date